NOVOB80 Stock Overview

Engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. More details

NOVOB80 fundamental analysis
Snowflake Score
Valuation	3/6
Future Growth	3/6
Past Performance	4/6
Financial Health	4/6
Dividends	3/6

Rewards

Trading at 45.6% below our estimate of its fair value

Earnings are forecast to grow 13.46% per year

Earnings grew by 25.8% over the past year

Risk Analysis

High level of non-cash earnings

Volatile share price over the past 3 months compared to the TH market

My Notes

Capture your thoughts, links and company narrative

Novo Nordisk A/S Competitors

Mega Lifesciences

SET:MEGA

฿30.1b

Johnson & Johnson

NYSE:JNJ

US$342.5b

Merck

NYSE:MRK

US$252.6b

Eli Lilly

NYSE:LLY

US$708.8b

Price History & Performance

Summary of share price highs, lows and changes for Novo Nordisk
Historical stock prices
Current Share Price	DKK 3.04
52 Week High	DKK 4.00
52 Week Low	DKK 2.92
Beta	0.20
1 Month Change	-19.58%
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-23.23%

Recent updates

Shareholder Returns

	NOVOB80	TH Pharmaceuticals	TH Market
7D	0.7%	-0.2%	-1.2%
1Y	n/a	2.1%	-3.9%

Return vs Industry: Insufficient data to determine how NOVOB80 performed against the TH Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how NOVOB80 performed against the TH Market.

Price Volatility

Is NOVOB80's price volatile compared to industry and market?
NOVOB80 volatility
NOVOB80 Average Weekly Movement	6.7%
Pharmaceuticals Industry Average Movement	4.3%
Market Average Movement	4.4%
10% most volatile stocks in TH Market	8.9%
10% least volatile stocks in TH Market	2.1%

Stable Share Price: NOVOB80's share price has been volatile over the past 3 months compared to the TH market.

Volatility Over Time: Insufficient data to determine NOVOB80's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1923	71,880	Lars Jorgensen	www.novonordisk.com

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas.

Novo Nordisk A/S Fundamentals Summary

How do Novo Nordisk's earnings and revenue compare to its market cap?
NOVOB80 fundamental statistics
Market cap	฿13.36t
Earnings (TTM)	฿452.29b
Revenue (TTM)	฿1.29t

29.6x

P/E Ratio

10.4x

P/S Ratio

Is NOVOB80 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
NOVOB80 income statement (TTM)
Revenue	DKK 270.58b
Cost of Revenue	DKK 41.51b
Gross Profit	DKK 229.07b
Other Expenses	DKK 134.35b
Earnings	DKK 94.72b

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

Feb 05, 2025

Earnings per share (EPS)	21.33
Gross Margin	84.66%
Net Profit Margin	35.01%
Debt/Equity Ratio	47.3%

How did NOVOB80 perform over the long term?

See historical performance and comparison

Dividends

1.6%

Current Dividend Yield

47%

Payout Ratio

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/01/10 16:39
End of Day Share Price	2025/01/10 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Novo Nordisk A/S is covered by 69 analysts. 23 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
null null	ABG Sundal Collier
Kamla Singh	AlphaValue
Gerhard Schwarz	Baader Helvea Equity Research